If You Invested in Avricore Health (AVCRF)
Looking for the current price? See the AVCRF quote & overviewWhat $1,000 or $10,000 in AVCRF Would Be Worth Today
Real historical value by amount invested and how long ago| If you invested | 1 year ago | 5 years ago | 10 years ago | Since Jul 27, 2015 |
|---|---|---|---|---|
| $1,000 | $471 -53% | $224 -78% | $42 -96% | $31 -97% |
| $10,000 | $4,710 -53% | $2,243 -78% | $420 -96% | $311 -97% |
Based on real historical closing prices through the latest market close. Past performance does not guarantee future results.
Custom Calculation
Choose your own date and amount for AVCRF$1,000 Investment Over Time
AVCRF vs S&P 500Year-by-Year Returns
AVCRF annual performance| Year | Start Price | End Price | Annual Return | Cumulative |
|---|---|---|---|---|
| 2017 | $0.15 | $0.27 | +80.0% | +80.0% |
| 2018 | $0.27 | $0.08 | -71.4% | -47.6% |
| 2019 | $0.08 | $0.01 | -81.9% | -90.5% |
| 2020 | $0.01 | $0.07 | +432.1% | -49.4% |
| 2021 | $0.07 | $0.12 | +66.3% | -15.9% |
| 2022 | $0.13 | $0.23 | +69.7% | +52.7% |
| 2023 | $0.24 | $0.11 | -54.2% | -25.3% |
| 2024 | $0.14 | $0.04 | -70.9% | -71.9% |
| 2025 | $0.04 | $0.05 | +26.1% | -67.5% |
| 2026 | $0.03 | $0.03 | +6.2% | -76.8% |
About Avricore Health
Healthcare · OTC Link
Avricore Health Inc. (OTCQB: AVCRF) is described as a pharmacy service innovator focused on acquiring and developing early-stage technologies aimed at moving pharmacy forward. The company is associated with the pharmaceutical preparation manufacturing industry and the broader manufacturing sector. It is a foreign private issuer for U.S. securities law purposes and files reports with the U.S. Securities and Exchange Commission.
According to company-focused editorials, Avricore Health pursues its mission by working with technologies that bring real-world health data and point-of-care testing into community pharmacy settings. The company emphasizes making actionable health information more accessible to everyone. Its approach is tied to trends in healthcare where patients, insurers, and healthcare providers are increasingly interested in data-driven care, faster diagnostics, and earlier disease detection.
HealthTab™ and point-of-care testing
Avricore Health’s flagship offering is HealthTab™, which is described as a wholly owned subsidiary and a turnkey point-of-care testing solution. HealthTab is presented as a product that delivers real-time results and is designed for use in community pharmacies. Editorial coverage notes that HealthTab has been evaluated at leading pharmacies in Canada, with North American expansion mentioned as a future direction in that context.
The company’s stated mission with HealthTab is to help create what it calls the world’s largest network of rapid-testing devices in community pharmacies. This aligns with the broader point-of-care testing (POCT) field, which focuses on performing diagnostic tests at or near the site of patient care rather than relying solely on centralized laboratories.
Business focus and sector context
Within the pharmaceutical preparation manufacturing industry, Avricore Health positions itself around pharmacy services and early-stage technologies rather than traditional large-scale drug manufacturing. The company’s activities, as described in the available materials, center on technologies that enable pharmacies to offer additional services linked to rapid testing and health data. This reflects pressures on pharmacies from regulators, competition, and industry dynamics, and the need for new service-based revenue opportunities highlighted in the referenced editorials.
Avricore Health’s focus on real-world data and rapid testing is framed as a response to rising healthcare costs and inconsistent outcomes. The company’s materials emphasize that real-world evidence and near-instant test results can support earlier detection of disease and more proactive patient engagement, which are themes repeatedly mentioned in the third-party coverage provided.
Regulatory reporting and foreign issuer status
Avricore Health Inc. files as a foreign private issuer with the SEC under Commission File Number 000-51848. The company submits Form 6-K reports for specific months, which can include certifications of interim filings, interim financial statements, management discussion and analysis (MD&A), and news releases. For example, a Form 6-K for the month of December 2025 lists interim financial statements and MD&A for a period ending September 30, 2025, along with related certifications. Another Form 6-K for November 2025 includes a news release titled “HealthTab to Power NHS Pilot.”
These filings indicate that Avricore Health continues to provide interim financial and narrative disclosures, as well as news releases, through the SEC’s EDGAR system. The presence of these filings also confirms that the company remains subject to ongoing reporting obligations as a foreign private issuer.
Geographic base
The SEC filings list Avricore Health Inc.’s principal executive office in Vancouver, British Columbia, Canada. This aligns with editorial references that describe Avricore Health as a Vancouver-based company. The company also trades on the TSX Venture Exchange under the symbol AVCR, in addition to its OTCQB listing as AVCRF.
Mission and strategic themes
Across the available descriptions, Avricore Health consistently highlights several themes:
- A focus on pharmacy service innovation, with an emphasis on early-stage technologies.
- A mission to make actionable health information more accessible to everyone.
- Development and commercialization of HealthTab™ as a turnkey point-of-care testing solution for pharmacies.
- An ambition to build a large network of rapid-testing devices in community pharmacies.
- Engagement with the broader shift toward real-world data and point-of-care testing in healthcare.
These themes position Avricore Health within a niche that connects pharmacy operations, diagnostic technology, and health data. The company’s communications and third-party editorials emphasize how point-of-care testing and real-time results can support earlier detection of disease and more proactive patient behavior.
Investor considerations
For investors researching AVCRF, the available information highlights that Avricore Health is active in the pharmacy services and point-of-care testing space, with HealthTab as its flagship offering. Its filings as a foreign private issuer on Form 6-K provide access to interim financial statements, MD&A, and selected news releases. Editorial coverage from investor-focused networks underscores the company’s emphasis on real-world data, rapid testing, and the role of pharmacies as sites for expanded health services.
Because the information provided focuses on business model descriptions and interim filings, potential investors may wish to review the company’s SEC submissions and other regulatory disclosures for detailed financial information, risk factors, and additional operational context.
Similar Stocks
See how related companies performed
Frequently Asked Questions
Avricore Health investment returns
How much would $1,000 invested in Avricore Health be worth today?
If you invested $1,000 in Avricore Health (AVCRF) 10 years ago on 2016-07-25, your investment would be worth $42 today, representing a -95.8% total return, growing at a compounded rate of -27.2% per year (CAGR).
Has Avricore Health outperformed the S&P 500?
Over the past 10 years, AVCRF returned -95.8% compared to +241.1% for the S&P 500, underperforming the benchmark by 336.9 percentage points.
What is Avricore Health's average annual return?
The compound annual growth rate (CAGR) of AVCRF over the past 10 years is -27.2%, growing at a compounded rate each year. Individual years vary significantly — AVCRF's best recent year was 2020 (+432.1%) and worst was 2019 (-81.9%).
Your Privacy is Protected
This calculator sends the symbol, date, and amount you enter to our server so we can fetch historical market data and render the result. We do not save those entries as a portfolio or account, but standard web server logs may still record the page request.
For informational and educational purposes only — not investment advice.
